ALNY - Alnylam Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow

Income Statement

Annual
All numbers in thousands
Revenue12/31/201812/31/201712/31/201612/31/2015
Total Revenue74,90889,91247,15941,097
Cost of Revenue1,802---
Gross Profit73,10689,91247,15941,097
Operating Expenses
Research Development463,261359,613352,360254,970
Selling General and Administrative424,518230,387119,38682,135
Non Recurring----
Others----
Total Operating Expenses889,581590,000471,746337,105
Operating Income or Loss-814,673-500,088-424,587-296,008
Income from Continuing Operations
Total Other Income/Expenses Net53,9999,21414,4795,935
Earnings Before Interest and Taxes-814,673-500,088-424,587-296,008
Interest Expense----
Income Before Tax-760,674-490,874-410,108-290,073
Income Tax Expense823---
Minority Interest----
Net Income From Continuing Ops-761,497-490,874-410,108-290,073
Non-recurring Events
Discontinued Operations----
Extraordinary Items----
Effect Of Accounting Changes----
Other Items----
Net Income
Net Income-761,497-490,874-410,108-290,073
Preferred Stock And Other Adjustments----
Net Income Applicable To Common Shares-761,497-490,874-410,108-290,073